Kapil, Ansh http://orcid.org/0000-0002-5079-6997
Spitzmüller, Andreas
Brieu, Nicolas
Haneder, Susanne
Shumilov, Anatoliy
Meier, Armin
Cecchi, Fabiola
Barkell, Alice
Harder, Nathalie
Mittermaier, Katrin
Hidalgo-Sastre, Ana
Alleze, Regina
Schick, Markus
Schmidt, Günter
Sade, Hadassah
Tsuchihashi, Zenta
Suto, Fumitaka
Gustavson, Mark
Barrett, J. Carl
Carroll, Danielle
Funding for this research was provided by:
AstraZeneca
Article History
Received: 11 December 2023
Accepted: 12 May 2024
First Online: 27 May 2024
Competing interests
: The authors declare the following competing interests: all authors were full-time employees of AstraZeneca Oncology R&D/Daiichi Sankyo Inc. at the time of their contributions to this work and received non-financial support (assistance with manuscript preparation) from Articulate Science and Helios Medical Communications. Additional disclosures are as follows: A.K. reports travel fees from AstraZeneca; pending patents; and ownership of AstraZeneca stock or stock options. A.Sp. and N.B. report pending patents. S.H reports travel fees from AstraZeneca and ownership of Daiichi Sankyo stock or stock options. A.Sh., A.M., K.M., N.H., R.A. and M.S. reports travel fees from AstraZeneca. F.C., A.B., and A.H.S. report ownership of AstraZeneca stock or stock options. G.S. reports pending patents, and ownership of AstraZeneca and Merck KGAA stock or stock options. H.S. and M.G. reports travel fees from AstraZeneca and ownership of AstraZeneca stock or stock options. Z.T. and F.S. report ownership of Daiichi Sankyo, Inc. stock or stock options. J.C.B. reports consulting fees from Corista and ownership of Daiichi Sankyo, Inc. stock or stock options. D.C. reports travel fees from AstraZeneca; pending patents; participation in data safety monitoring advisory boards for AstraZeneca; and ownership of AstraZeneca stock or stock options.